While GLP-1 receptors are expressed in hypothalamic and reproductive pathways, human data do not demonstrate direct infertility effects
It can also be produced by neurons and microglial cells (Kappe et al., 2012)
Updated for 2026 with CMS-0057-F rule, Medicare GLP-1 Bridge program, MFN pricing deals, oral Wegovy approval, and AHIP reform pledges
This medicine has shown hopeful safety profiles in animal studies and early clinical trials for different diseases, however, its safety for managing ED in humans is not well-established
We monitor the latest FDA updates on all our peptide therapies and can keep you updated on retatrutide
KPV demonstrates a biphasic dose-response curve with maximal NF-B inhibition at 110 M and diminishing returns above 50 M, making dosing precision critical for reproducible research outcomes